Sign in

    Chris LoBianco

    Vice President of Equity Research at TD Cowen

    Chris LoBianco is a Vice President of Equity Research at TD Cowen, specializing in coverage of biotechnology and pharmaceutical companies such as Novavax, as well as analyzing drug pricing trends across the industry. He has contributed to TD Cowen’s annual drug pricing survey and is recognized for his industry insights, collaborating on reports that capture insights from a quarter of the U.S. drug spend and forecast sector price dynamics. LoBianco began his career as an Associate Consultant at Boston Consulting Group before joining TD Securities (USA) LLC, where he rose to his current role in 2024. He maintains FINRA registration and relevant securities licenses to support his research coverage and client communications.

    Chris LoBianco's questions to NOVAVAX (NVAX) leadership

    Chris LoBianco's questions to NOVAVAX (NVAX) leadership • Q2 2025

    Question

    Chris LoBianco of TD Cowen asked about the company's confidence in the post-marketing Phase 4 trial and whether Novavax is open to acquiring or in-licensing external clinical-stage candidates to supplement its pipeline.

    Answer

    President, CEO & Director John Jacobs clarified that the company's current strategy is focused on out-licensing its technology and advancing its internal pipeline, rather than in-licensing or acquiring external assets. He stressed the priority of optimizing existing partnerships with Sanofi, Takeda, and Serum. EVP, CFO & Treasurer Jim Kelly reinforced this, stating the goal is to drive value by enabling more partners to innovate using Novavax's differentiated Matrix-M technology platform.

    Ask Fintool Equity Research AI